Cantor kept its favorable rating and $15-per-share target for Trulieve, with the target suggesting 45.9% potential upside. Since both were unchanged and no new company results were reported, this does not change the company's outlook.
A repeated analyst view does not show a change in Trulieve's sales, costs, or operations. The story reports no new company results or action, so it does not change how we read the business.
Follow Trulieve Cannabis Corp. (TRLV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TRLV